OpGen Completes CDC Contract to Develop Clinical Support Mobile-Based Tools for Antimicrobial Stewardship and Infection Contr...
December 18 2018 - 7:30AM
OpGen, Inc. (NASDAQ: OPGN) today announced that it has provided the
final report for completion of the contract from the Centers for
Disease Control and Prevention (CDC) to develop smartphone-based
clinical decision support solutions for antimicrobial stewardship
(AMS) and infection control in low- and middle-income countries.
The one-year $860,000 award began September 30, 2017 and funded
development and evaluation of cloud-based mobile software. OpGen
worked with partners ILÚM Health Solutions, LLC (“ILÚM”), a wholly
owned subsidiary of Merck’s Healthcare Services and Solutions, and
Universidad El Bosque (UEB) of Bogota, Colombia led by Maria
Virginia Villegas, M.D., M.Sc.
“OpGen was honored to work with the CDC and our
partners to help address this urgent global need,” said Evan Jones,
Chairman & CEO of OpGen. “Improving antimicrobial stewardship
globally has been identified by the CDC, the World Health
Organization (WHO) and governments worldwide as a core activity in
the fight to prevent and contain the spread of multidrug-resistant
pathogens.”
OpGen chose to partner with ILÚM based on its
advanced clinical decision support capabilities that enhance
OpGen’s commitment to improve antimicrobial stewardship and
optimize infectious disease management. “OpGen is leveraging
ILÚM’s Insight, a cloud- and mobile-based solution that integrates
electronic patient data and local empiric treatment guidelines”,
noted Mr. Jones. “Our ecosystem results in enhanced selection
of both empiric and definitive therapy, which includes an
unparalleled arrival to definitive choice. While our
collaborative approach to solving these public health challenges is
repeatable in other economically-challenged countries, our ability
to optimize US precision antibiotic therapy is equally compelling.”
“Dr. Villegas and the UEB team guided the
customization of the AMS software for the needs of low- and
middle-income countries. They also worked with OpGen and ILÚM
to deploy the software in three medical sites in Colombia to assess
the effectiveness of the effort. Through this initial pilot,
we gained experience and positive results to support the expansion
of this important initiative further,” continued Mr. Jones. “The
three sites from the project intend to continue using the Insight
solution and we are in discussions with ILÚM to establish a
distribution relationship for Colombia and the region.”
About OpGenOpGen,
Inc. is harnessing the power of informatics and genomic
analysis to provide complete solutions for patient, hospital and
network-wide infection prevention and treatment.
About ILÚMILÚM Health
Solutions is a provider of technology and services to support
infectious disease management, clinical decision-support and
precision antibiotic therapy. ILÚM is part of Healthcare Services
& Solutions, LLC, a wholly-owned subsidiary of Merck & Co.,
Inc. Its Insight solution and other portfolio products are
commercially available and in use in major health systems.
For more information, visit www.ILÚMhealthsolutions.com.
Forward-Looking StatementsThis
press release includes statements relating to OpGen’s expectations
regarding the use of the Insight products in the future in other
economically-challenged countries. These statements and other
statements regarding OpGen’s future plans constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, and are intended to qualify for the safe
harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
OpGen’s control, and which may cause results to differ materially
from expectations. Factors that could cause results to differ
materially from those described include, but are not limited to,
OpGen’s ability to successfully implement the awarded
contract. For a discussion of the most significant risks and
uncertainties associated with OpGen's business, please review its
filings with the Securities and Exchange Commission (SEC). You are
cautioned not to place undue reliance on these forward-looking
statements, which are based on OpGen’s expectations as of the date
of this press release and speak only as of the date of this press
release. OpGen undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
OpGen Contact:Michael FarmerVice President,
Marketing240-813-1284mfarmer@opgen.comInvestorRelations@opgen.com
Investor Contact:LHA Investor RelationsKim
Sutton Golodetz212-838-3777kgolodetz@lhai.comorBruce
Voss310-691-7100bvoss@lhai.com
Press Contact:Matthew BretziusFischTank
Marketing and PRmatt@fischtankpr.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Apr 2024 to May 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From May 2023 to May 2024